An innovative biotherapy against chronic metabolic diseases
ObAdEx: a paradigm change for the treatment of metabolic obesity
Obesity is characterized by a disruption in the balance existing between white adipose tissue (WAT) and beige adipose tissue (BAT): WAT accumulates and becomes dysfunctional, while BAT disappears or is heavily reduced. Nonetheless, BAT is considered as the "good" adipose tissue that burns the excess of energy and regulates metabolism by secreting specific factors, thus preventing chronic metabolic diseases such as type-2 diabetes and NASH. Restoring BAT mass in obese patients could counteract obesity-driven metabolic disorders.
We have developed a breakthrough process to overcome the barrier of the ex vivo culture of viable and functional human adipose tissue for clinical applications. Our technology allows to transform WAT into a functional and vascularized BAT biotherapy called ObAdEx. The process for ObAdEx production is tailored for clinical applications and upscaling for industrial production. Transplantation of ObAdEx biotherapy in preclinical models has revealed that the product is viable, revascularized and displays a BAT signature several weeks after grafting. Preclinical studies on disease in vivo models are ongoing.
This technology is protected by 2 international patent families and a unique know-how from more than 30 years of experience in stem cells and adipose tissue. ObAdEx project has received DeepTech label by BpiFrance.